.Merck trumps earnings assumptions, raises purchases outlook on powerful need for leading drugs like Keytruda CNBCMerck & Co. (MRK United States) Trumps Revenue Projections as Keytruda Sales Growth BloombergMerck Stock: Pharma Giant Posts Strong Outcomes, But Outlook Falls Short Client's Organization DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck trumps profit and sales assumptions surrounded by Keytruda strong point, but supplies mixed full-year expectation MarketWatch.